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ABSTRACT 
Objective: To measure the relative risks of Barrett’s esophagus (BE) associated with 
demographic factors, measures of adiposity and smoking among patients with gastroesophageal 
reflux disease (GERD). 
Methods: Patients newly diagnosed with specialized intestinal metaplasia (SIM) (n=197) were 
compared to patients with GERD (n= 418) in a community clinic-based case-control study.  Case 
sub-groups included those with any visible columnar epithelium (VBE) (n=97), and those with a 
long segment (=2cm) of columnar epithelium (LSBE) (n=54).  
Results: Risks increased with older age (adjusted odds ratio (aOR) per decade for SIM=1.3, 95% 
confidence interval (CI)= 1.1-1.5; VBE aOR=1.4 ,CI=1.1-1.6; LSBE aOR=1.5, CI=1.2-1.9), 
male gender (SIM aOR=1.5, CI=1.1-2.2; VBE aOR=2.7, CI=1.6-4.5; LSBE aOR=3.9, CI=1.9-
8.1) and possibly Asian race. Increased risk of BE in particular was observed with high waist-to-
hip ratio (WHR, male high: =0.9, female high: =0.8) (SIM aOR=1.3, CI=0.9-2.1; VBE aOR=1.9, 
CI=1.0-3.5; LSBE aOR=4.1, CI=1.5-11.4).  These associations were independent of body mass 
index (BMI) for the VBE and LSBE case groups but not for SIM which was the only case group 
in which BMI was a significant risk factor.  Ever smoking cigarettes increased risk similarly for 
all case groups (SIM aOR=1.8, CI=1.2-2.6; VBE aOR=1.6, CI=1.0-2.6; LSBE aOR=2.6, CI=1.3-
4.9), although dose response relationship was not detected for duration or intensity of smoking. 
Conclusions: Older age, male gender and history of smoking increased risk of SIM and BE 
among GERD patients independent of other risk factors for BE. Central adiposity was most 
strongly related to risk of VBE and LSBE. These results may be useful in development of risk 
profiles for screening GERD patients. 
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INTRODUCTION 
Gastroesophageal reflux disease (GERD) is a major health problem in North America and 
Europe, with a high prevalence and considerable consequences for those affected.  The 
prevalence of GERD, defined as at least weekly heartburn and/or acid regurgitation, is estimated 
to be 10–20% in the Western world (1).  Treatments are expensive (2;3), costing the US 
approximately $9 billion annually (4), and those with frequent GERD symptoms experience a 
decrease in the heath-related quality of life (5;6).  Furthermore, GERD is a strong risk factor for 
esophageal adenocarcinoma (EA) (7;8) and its precursor, Barrett’s esophagus (BE) (9-12). As 
the incidence of EA has increased in the US more rapidly than any other cancer over the last 30 
years (13-16), it is particularly important to identify factors which may influence the conditions 
that lead to its development: GERD and BE.    
Among persons with long-standing GERD symptoms, only about 10 – 15% actually develop BE 
in their lifetimes; among those who do, most do not progress to EA. Therefore, there must be 
other cofactors modulating the reflux-related chronic inflammatory effects on the esophageal 
epithelium.  Case-control studies comparing BE cases to general population controls have 
identified abdominal obesity and cigarette smoking as possible risk factors for BE independent 
of GERD symptoms (17-19); however much less is known about factors that place GERD 
patients at higher risk for BE.  Identification of such risk factors could help identify which 
GERD patients to endoscope, and could add to the prediction models being developed for this 
purpose (20).  In this report, we explore the association between BE and demographic factors, 
various anthropometric measures, and smoking history in a community clinic-based case-control 
study among patients with chronic GERD symptoms. 
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PATIENTS AND METHODS 
Study Participants 
Cases were selected from among western Washington residents aged 20-80 years without 
previously-diagnosed BE who underwent an upper endoscopy for the investigation of  chronic 
GERD symptoms (e.g. heartburn, acid regurgitation, atypical chest pain, and/or belching), at one 
of five community gastroenterology clinics between October 1, 1997 and September 30, 2000, as 
described previously (18). Briefly, potential participants were recruited in conjunction with their 
endoscopy visit. Cases were defined as those with specialized metaplastic epithelium (SIM) on at 
least one of four standard four-quadrant biopsies taken just distal to the squamocolumnar 
junction for the purposes of this study. These were evaluated by one of three University-based 
pathologists masked to endoscopy findings.  Of the 1185 persons who consented to provide 
biopsies, SIM was found in 208 (17.6%). Of these patients, 193 (92.8%) were successfully 
interviewed.  During the endoscopy, physicians recorded the presence and length of any visible 
columnar epithelium.  Cases were subsequently classified into one to three of the following 
progressively exclusive groups: 1. SIM cases (i.e., all cases), 2. SIM and visible evidence of 
columnar epithelium (VBE), and 3. SIM and visible column epithelium greater than 2 cm (long 
segment BE, LBSE).  The second two subgroups adhere to the case definition of BE as described 
by the American College of Gastroenterology  (21), while the most inclusive group,  SIM, is 
consistent with the concept of “ultra-short segment BE" (22-24).  Eighteen cases (9.3%) were 
simultaneously diagnosed with adenocarcinoma (n=2) and/or dysplasia (n=0 high grade; n=16 
low grade); these were included in all analyses.  
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A random sample of approximately 50% of the patients undergoing endoscopy for reflux 
symptoms but who were biopsy-proven negative for SIM, were chosen to be used as GERD 
controls. These were frequency-matched to the distribution of cases on the month of biopsy and 
clinic. Of the 463 patients selected to be GERD controls, 419 (90.8%) were successfully 
interviewed.   
This study was approved by the institutional review board of the Fred Hutchinson Cancer 
Research Center, Seattle WA. 
Data collection 
Cases and GERD controls underwent structured interviews by trained staff in their homes or 
another requested location approximately 1-2 months after endoscopy.  The interview, which 
took about 45 minutes to complete, covered demographic characteristics, smoking and 
alcohol use history, diet, and relevant health and medication history. Interviewers measured 
participants’ height and weight, as well as waist, hip and thigh circumference using an 
established protocol (25).  All but two cases completed the portion of the interview with 
anthropometric measurements. Of the GERD controls, five participants had partial 
measurements done and three refused.  
Antibody levels to Helicobacter pylori were available for the first 50 cases and 97 GERD 
controls using a total antibody latex agglutination assay kit (Orion Diagnostica, Espoo, 
Finland)(26). 
Statistical Analyses 
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Multivariate unconditional logistic regression with robust standard errors was used to calculate 
adjusted odds ratios (OR) and 95% confidence intervals (CI) using Stata/SE (version 9.1) (27).   
Demographic factors and measurements of adiposity and smoking were divided into potential 
risk categories, with the low risk category used as the referent group. Demographic factors 
examined included age assessed continuously and categorically (<50 years old/ 50+), gender, 
race (White/Black/Asian American/Other) and education (high school or less/technical 
school/college or more). Measures of adiposity examined included BMI (kg/m2), waist 
circumference (cm) (WC), WHR and weight to thigh ratio (WTR).  The categories used for BMI 
(< 25 kg/m2/ 25-29.99/ 30 +), as well as the gender-specific categories used for WC (Male 
Low/Medium/High: <93 cm/94-101.99/102+; Female Low/Medium/High: <79cm/79-87.99/88 
+) and WTR (Male Low/Medium/High: 0.97-1.66/1.66-1.80/1.80-2.72; Female 
Low/Medium/High: 1.02-1.42/1.42-1.61/1.62-2.4) were those used and discussed in a recent 
report from this study (18).  In that report, the WHR high-risk category was 0.9+ for males and 
0.85+ for females.  However, when examining the risk of BE by 0.05-increments for this 
investigation, substantial risk of BE was found in lower values of WHR for females, though not 
in males.  Thus, in this investigation the high-risk categories for the binary categorization of 
WHR are 0.9+ for males and 0.8+ for females.  We also present the relative risks by 0.05-
increments of WHR.   
History of cigarette use was analyzed in four different forms: ever/never binary, 
current/ever/never categorical, total pack-years in three categories as defined by the median of 
the entire study population (never/<13.5/ 13.5+), and years since cessation.  Alcohol 
consumption was evaluated for beer, wine and liquor separately based on a lifetime-averaged 
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frequency of drinks (weekly/<weekly-daily/daily+).  Heartburn and acid regurgitation frequency 
were categorized similarly. 
The potential confounding effects of age, gender, race and education level as well as design 
variables, clinic and time period of endoscopy (1998-1999/2000-2002), were assessed, and 
factors that made more than a 10% difference in the ORs for an appreciable number of 
associations were included in adjusted models, along with measures of obesity and cigarette 
smoking.  Trend tests were based on using continuous measures in the logistic regression models 
for age, BMI, WC, WHR, WTR, pack-years and years since smoking cessation, with all but age 
considered in natural logarithm form in addition to untransformed continuous. Stratified ORs 
presented are based on logistic regression models that included interaction coefficients between 
the subgroup classification of interest and WHR.  
RESULTS 
Table 1 presents selected socio-demographic characteristics of cases and GERD controls.  Of 
197 cases with SIM, 97 were VBE cases and, of those, 54 were cases of LSBE.  All participants 
reported at least one GERD symptom. The most common symptom was heartburn (92% of both 
cases and GERD controls), with 77% GERD controls and 76% of cases reporting a frequency of 
at least once per week. 
Older age and male gender were associated with increased risk for each of the case groups (Table 
2).  Relative risks associated with older age were quite similar across case groups (age per 
decade adjusted odds ratio (aOR) for SIM=1.3, 95% confidence interval (CI)= 1.1-1.5; VBE 
aOR=1.4 ,CI=1.1-1.6; LSBE aOR=1.5, CI=1.2-1.9).  On the other hand, the strength of the 
association with male gender increased from SIM to LSBE.  Compared to White participants, 
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Asians were at increased risk for all three case groups, whereas those of African or other 
ancestry were at reduced risk. Similar results for race and age were found for SIM-only cases, 
(i.e., the 96 participants with SIM who had no visible columnar epithelium); however, in this 
group there was no association seen with gender.  
Among the measures of adiposity, WHR and WTR were the strongest predictors of risk for both 
the VBE and LSBE case groups (Table 2).  The associations with BMI and WC were not as 
strong and generally lacked statistical significance.  An exception was that among all SIM cases 
there was a significant positive trend for BMI.  This could be wholly attributed to a moderately 
strong association with BMI in the SIM-only case group (BMI 25-29.99 aOR= 2.3, CI= 1.1-4.5; 
BM =30 aOR= 2.7, CI=1.4-5.4.) 
When WHR and BMI were modeled simultaneously, the association between WHR and all SIM 
cases lost strength (aOR=1.1, CI = 0.7– 1.8) and BMI estimates were relatively unaffected. In 
contrast, WHR’s association with VBE (aOR= 2.0, CI = 1.0-3.9) and LSBE (aOR= 4.0, CI = 1.4 
– 11.6) remained strong and the estimates for BMI’s association with these case groups were 
reduced to near unity.  Similar results were seen when WTR was used in place of WHR.  None 
of the associations presented in the Table 2 were appreciably affected when adjusted for race, 
education, time period of endoscopy, frequency of heartburn, acid regurgitation, or alcohol 
consumption.   
Figure 1 illustrates that for most gender-specific case groups, after the initial increase, there was 
not a substantial further increase in the ORs for each of the 0.05-increment WHR.  When 
modeled continuously either as natural log continuous (Table 2), untransformed continuous or in 
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0.05-increments, the trend tests were not statistically significant.  A similar threshold by gender 
was seen when WTR was modeled.   
The associations between WHR and risk of all three case types tended to be stronger among 
those with a BMI of 25 or greater and those with at least weekly GERD symptoms (Table 3).  In 
contrast, there was no apparent pattern in variation of ORs in strata defined by age, gender, 
smoking history or race (race data not shown). None of the variations in OR described in Table 3 
was statistically significant.     
A history of ever smoking cigarettes was significantly associated with each of the case groups 
when adjusted for age, gender, WHR and clinic (Table 4), with little evidence of a dose-response 
relationship when smoking was measured in pack-years (all p-values of trend tests = 0.05).  
Smoking cessation was not observed to decrease risk. These estimates were not appreciably 
different when further adjusted for race, education, time period of endoscopy or frequencies of 
heartburn, acid regurgitation or alcohol consumption.  In contrast, in the SIM-only case group, 
there was weak evidence of a dose-response relationship:  relative to nonsmokers, current 
smokers were at higher risk (aOR=2.3, CI= 1.2-4.5) than former smokers (adjusted OR = 1.9, CI 
= 1.1-3.2) and the trend test for pack-years was statistically significant (p<.0.01). 
There was no association between any of the case groups and Hispanic origin, education or any 
type of alcohol consumption when adjusted for age, gender, cigarette smoking, WHR and clinic 
(data not shown).  In an unadjusted analysis, drinking beer daily or more frequently was 
associated with all case groups; the strongest association was in the LSBE group (crude OR= 2.7, 
CI=1.3 – 5.7).  However, adjustment substantially reduced the strength and statistically 
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significance of these associations (e.g. LSBE adjusted OR= 1.2, CI=0.5-3.1), with gender and 
cigarette smoking history as the major confounding factors. 
In the small number of cases (SIM n=50; VBE n=19, LSBE n=10) and GERD controls (n=97) in 
whom antibody levels had been measured, WHR and male gender were associated with risk 
among those who were H. pylori negative (WHR OR=2.1, CI=0.9-5.6; Male OR=1.6 , CI=0.7-
4.1), but not those who were H. pylori positive (WHR OR=1.1, CI=0.4-3.5; Male OR= 0.9, 
CI=0.3-2.6) in unadjusted analyses.  In contrast, the association between SIM and cigarette 
smoking history (ever/never) or age (<50/50+ or by decade)  were similar in the two groups.   
DISCUSSION 
In this community clinic-based case-control study we observed a number of factors that 
increased risk for SIM and BE among patients with chronic GERD symptoms. Older age, male 
gender and possibly Asian race were associated with increased risk independent of other 
proposed risk factors for BE.  Measures of central adiposity, WHR and WTR, were also 
associated with case status, with relative risk increasing from SIM to VBE and from VBE to 
LSBE. Risk did not increase appreciably once a gender-specific threshold was reached. The 
association with WHR was independent of BMI for VBE and LSBE cases, whereas in the SIM 
case group the relationship lost strength when adjusted for BMI. The relationship between BE 
and WHR was stronger in patients with more frequent GERD symptom and those with BMI’s 
greater than 25 kg/m2.  We observed a moderately increased risk of BE with a history of cigarette 
smoking, but little evidence of a dose-response relationship with intensity or duration of 
smoking, and no evidence of decreased risk with cessation.  
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BE is traditionally thought of as a disease of middle-aged and older, white men (28;29) and most 
of our results support this demographic profile.  We are unaware of other studies that performed 
a multivariate analysis to investigate these demographic factors among patients with chronic 
GERD symptoms, though the increasing risk of BE associated with increasing age we observed 
is consistent with three recent studies that compared BE cases to patients undergoing endoscopy 
for any indication  (30-32). Furthermore, two of these studies appear to support our finding that 
the relationship with age may not change by case group, with one study in Sweden reporting 
statistically significant adjusted ORs for age of 1.05 per year (approximately 1.6 per decade) for 
patients in case groups with similar definitions to our SIM and VBE groups (31) and another in 
the United Kingdom (30) reporting an statistically significant adjusted OR of 1.03 
(approximately 1.3 per decade) in an LSBE case group.   
Male gender was identified as a strong risk factor in the United Kingdom study (30), as well as 
in a multi-center investigation in the US (32), which also used LSBE as its case definition.  In 
contrast, no significant relationship between gender and risk of SIM and VBE was observed in 
the Swedish study (31).  Male gender as a risk factor for BE is also supported by the 
predominance of males among BE cases reported in numerous studies, regardless of whether BE 
is defined by SIM or columnar epithelium-line esophagus (33).  The increase in strength of the 
association with male sex from SIM to VBE and from VBE to LSBE in our study was similar to 
that observed in data presented by Hirota et al (34), in which there was an increase in the 
male/female sex ratio from short-segmented BE cases to LSBE.  In addition, reports have noted 
increased presence and severity of erosive esophagitis among males, suggesting that males may 
experience increased severity of reflux or susceptibility to its immediate complications(35; 36).    
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Although our study population was mainly White, consistent with BE studies among patients 
undergoing endoscopy (32; 37), we detected lower risk for Blacks for SIM and no Black case 
participants with VBE.  That participants of Asian origin appeared to be at higher risk for BE 
than Whites was unexpected.  Despite the small number of Asian participants in our study, this 
finding was statistically significant in the overall (SIM) group and increased risk was found in all 
three case groups.  This contrasts with two other studies done in US populations in which Asian 
Americans were at lower risk of BE (32; 38).  It is possible that the findings in the SIM group are 
due to its heterogeneity, as it likely includes a substantial proportion of cardia metaplasias, for 
which Asians are likely at higher risk due to for H. pylori pangastritis.  We note that the findings 
in the VBE and LSBE groups are particularly limited by small sample size, and suggest that 
further investigation is needed into risk of SIM and BE associated with Asian race. 
Central adiposity was a risk factor for SIM and BE among our study population with chronic 
GERD symptoms.  The strength of the associations between either WHR or WTR and the BE 
case groups were not as strong as we found in our study comparing these BE cases to population 
controls (18), which is consistent with Corley et al’s (17) results comparing VBE cases to GERD 
and population controls using WC and WTR as measures of central adiposity.  This suggests that 
central adiposity plays a role in at least two steps of EA disease progression: from healthy to 
chronic GERD, and from GERD to BE.  Comparing VBE cases to GERD controls, Corley et al. 
also found evidence of a trend of increasing risk with increasing WC, with no evidence of a 
threshold effect.  Interestingly, this threshold effect was observed for both WC and WTR in the 
analysis with population controls as the comparison group.       
In terms of BMI, evidence from this investigation, and others including a recent meta-analysis by 
Cook et al (17;31;33;39), strongly suggests that BMI is not a risk factor for BE among those 
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undergoing endoscopy.  However, the trend seen for BMI in the SIM-only case group, 
independent of WHR, suggests that BMI plays a role in early in the development of BE.  
Alternatively, as discussed above, this association may result from the heterogeneity of the SIM 
group, as distinguishing metaplasia of the gastric cardia from metaplasia of the esophagus and 
gastroesophageal junction using clinical or histopathological criteria can be problematic.  Thus, 
if measures of central adiposity are causally related to development of BE among those with 
chronic GERD, but not to gastric cardia metaplasia, then one would expect the strongest 
associations to be found in the most specific case group: LSBE, as is evident in these data. 
Another approach to addressing the heterogeneity of the overall case group was our exploratory 
analysis focused on the H. pylori negative SIM cases, under the assumption that H. pylori 
positive cases were more likely to represent H. pylori-induced gastric cardia metaplasia. The 
results were consistent with this line of reasoning: among H. pylori negative cases, the 
association between risk of SIM and WHR was strong, whereas there was no association in the 
H. pylori positive group. It is also possible that the effect of central adiposity on the risk of SIM 
is less among persons with H. pylori gastritis due to less acidic refluxate (40). This difference by 
H. pylori status was also seen to a lesser extent in the association between SIM and gender, but 
not the association with age or cigarette smoking.  Regarding gender, these observations are 
consistent with the lack of gender association with gastric cardia metaplasia as reported by El-
Serag, et al. (41). These observations should be interpreted cautiously, though, as they are based 
on a small number of participants with antibody measurements and were analyzed in the SIM 
group, which is the least specific case group. 
The stronger association seen between WHR and BE in the subgroup of participants with higher 
BMI (Table 4) suggests that central adiposity and obesity may act together in increasing risk of 
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BE development. Thus, those chronic GERD patients with both a high BMI and significant 
central adiposity may be a potential targets for screening and prevention efforts.  Another 
subgroup that may be important is those with high WHR and frequent reflux symptoms. The 
potential interaction between the two among GERD patients is consistent with studies comparing 
either BE or EA cases to population controls (18;19). 
One possible biologic explanation for the relationship between BE and central adiposity is that 
the adipocyte's extensive metabolic activity may play a role in promoting BE and EA.  A number 
of bioactive substances (adipokines) are produced in excess of normal in visceral fat, including 
free fatty acids, leptin and inflammatory cytokines (42-44).  One consequence of this metabolic 
activity, particularly the production of fatty acids, is the development of insulin resistance 
(45;46) and resulting hyperinsulinemia, which can have direct effects on tumor development by 
promoting proliferation and inhibiting apoptosis and increasing IGF bioavailability (47).  
Adiponectin is found in decreased concentrations among overweight persons, and it has been 
negatively correlated with a number of obesity related cancers (48), perhaps due to the absence 
of its anti-inflammatory effects (49;50).  Pro-inflammatory cytokines and receptors, such as IL-6, 
TNF-alpha and leptin, are produced in significant amounts by adipocytes, particularly those in 
the visceral compartment (51-56). Leptin can also promote cancer via mitogenic and angiogenic 
mechanisms (57).  Comparing BE cases to population controls, Kendall et al (58) observed an 
association between leptin and BE independent of BMI in males but not females.  In a smaller 
pilot analysis, they found no relationship between BE and adiponectin for either gender.  Given 
that there is evidence of a relationship between central adiposity and BE risk in women, it seems 
that more research is needed to investigate the apparently discrepant results. 
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Our results regarding smoking, including the lack of dose-response relationship with increasing 
cumulative exposure and strength of estimates, are consistent with recent case-control studies 
based on population controls (18;19). Although, cigarette smoking was found to be significantly 
associated with each of the case groups that included those with visible evidence of columnar 
epithelium, it did not show a pattern of increasing risk by case group, as was found by Johnasson 
et al. (31).  This and the dose-response seen in the SIM-only case group suggests that it is a risk 
factor for metaplasia of the gastric cardia (59) in addition to BE.   
Strengths to our study include its design, breadth and depth of risk factors measured, 
standardized case classification and clinic-matched controls that were quite similar to cases in 
reporting of chronic GERD symptoms. This study is one of the first to examine the relative risk 
of BE among individuals with chronic GERD and multiple measures of overweight and central 
adiposity, including BMI, WC, WHR and WTR.  Furthermore, we were able to classify cases by 
their endoscopic appearance, as well as histologically through a standardized protocol, which 
included four quadrant biopsies interpreted by a small number of university-based pathologists.   
There are potential limitations as well.  It is possible that GERD patients receiving an endoscopy 
and agreeing to go undergo our initial screening process, may not be representative of all GERD 
patients.  Although our participation rate was high ( >90% ) among cases and GERD controls 
that underwent the initial screening process, we were unable to determine the rate of refusal 
among all endoscopy patients at the participating clinics and whether those not included differed 
in some way to the cases studied.  While it was not always feasible to blind the interviewers as to 
case status, they were not told of the specific hypotheses that would be examined, and it seems 
unlikely that their knowledge of case status biased the interview or physical measurements in 
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important ways.  Also, we had limited sample size for some of our analyses, particularly those 
regarding Asian race and results stratified by H. pylori status. 
We conclude that central adiposity is a risk factor for BE among GERD patients, suggesting that 
it may used as a factor in screening for endoscopy, perhaps more effectively in patients that also 
have more frequent GERD symptoms and/or have higher BMIs.  We also conclude that at least 
some of the effects of older age and male gender on risk of esophageal adenocarcinoma manifest 
themselves in the transition from GERD to BE, possibly via increased severity of reflux or 
increased susceptibility to its effects.  A history of cigarette smoking also predicted risk of BE, 
although we found no evidence of increased risk with increasing cumulative exposure, and no 
evidence of decreased risk with smoking cessation. These observations underscore the need for 
additional research focused on developing risk profiles for screening GERD patients that include 
age, sex, smoking and central adiposity, as well as continued research in identification of the 
mechanisms underlying obesity’s role in promoting BE and EA. 
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STUDY HIGHLIGHTS 
1) What is current knowledge? 
 
Barrett’s esophagus (BE) markedly increases risk of esophageal adenocarcinoma 
Reflux is a key risk factor, but only a small percentage develop BE 
Obesity and smoking act independently of reflux in increasing BE risk in the general 
population 
Little is known about predictors of BE among those with reflux 
2) What is new here? 
Among persons with reflux: 
Risk of BE increased by 30-50% per decade of age 
Most of the male excess of BE occurs in the step from reflux to BE 
Central adiposity substantially increases risk of BE 
There is a threshold effect of adiposity rather than a dose-response relationship 
Central adiposity and reflux act synergistically in causing BE 
History of smoking increases risk modestly   
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Figure 1. Odds ratios1 for associated with waist-to-hip ratio by case group and gender. 
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1Adjusted for age, cigarette smoking history and clinic  

Table 1. Socio-demographic characteristics of Barrett’s esophagus cases and GERD controls   
Cases (n=193)
 
GERD Controls (n=418)
Characteristic No. (%)  No. (%) 
Age    
20-39 27(14.0)  97(23.2) 
40-49 49(25.4)   118(28.2) 
50-59 57(29.5)  105(25.1) 
60-80 60  (31.1)  98(23.4) 
Sex    
Male 118(61.1)  214(51.2) 
Female 75 (38.9)  204(48.8) 
Race
  
White 172 (89.1)  374(89.5) 
Black or African 3 (1.6)  18(4.3) 
Asian Americans 9 (4.7)  6(1.4) 
American Indian/Eskimo 3 (1.6)  4(1.0) 
Other/Unknown 6 (3.1)  16(3.8) 
Hispanic    
Yes 9(4.7)  12(2.9) 
No 184 (95.3)  405(96.9) 
Unknown 0(0.0)  3(0.5) 
Education Level   
High School or less 49(25.4)  103(24.6) 
Technical School 9(4.7)  20(4.8) 
College or more 135(70.0)  293(70.1) 
Unknown 0(0.0)  2(0.5) 
Income Level    
Under 45,000 57(29.5)  146(35.0) 
45,000-74,999 56(29.0)  116(27.8) 
75,000+ 61(31.6)  128(30.6) 
Unknown 19(9.8)  28(6.7) 
Table 2. Odds ratios (OR) and trend tests for Barrett’s esophagus associated with demographic characteristics and 
measures of adiposity by case group   
SIM
 
VBE  LSBE 
Characteristic 
No. of  GERD 
Controls 
No. of 
Cases OR (95% CI) P7 
No. of 
Cases OR (95% CI) p 
No. of 
Cases OR (95% CI) p 
Age1
   
<0.001   0.001   0.001 
<50 215 76 1  35 1  20 1  
=50 203 117 1.6(1.1-2.4)  62 1.8(1.1-3.0)  34 1.8(0.9-3.3)  
Gender2 0.020   <0.001   <0.001 
Female 204 75 1  26 1  11 1  
Male 214 118 1.5(1.1-2.2)  71 2.7(1.6-4.5)  43 3.9(1.9-8.1)  
Race2 0.069   0.116   0.612 
White 374 172 1  91 1  53 1  
Black 18 3 0.5(0.1-1.9)  0 -  0 -  
Asian 6 9 3.9(1.3-11.6)  4 4.3(0.9-20.1)  1 2.0(0.1-31.0)  
Other 10 5 0.8(0.2-3.3)  1 0.3 (0.03-3.6)  0 -  
BMI3 (kg/m2) 0.011   0.294   0.057 
<25 114 37 1  25 1  11 1  
25-29.99 153 75 1.3(0.8-2.2)  35 0.9(0.5-1.6)  21 1.2(0.5-2.6)  
=30 146 79 1.7(1.1-2.7)  37 1.1(0.6-2.1)  22 1.5(0.7-3.4)  
Waist Circumference3,4 0.067   0.307   0.071 
Low 114 36 1  19 1  9 1  
Medium 115 59 1.5(0.9-2.6)  30 1.6(0.8-3.1)  15 1.7(0.7-4.2)  
High 186 96 1.6(1.0-2.6)  48 1.7(0.9-3.1)  30 2.3(1.1-5.2)  
Waist-to-hip ratio3,5
      
Low 121 39 1 0.556 14 1 0.281 4 1 0.015 
High 294 152 1.3(0.9-2.1)  83 1.9(1.0-3.5)  50 4.1(1.5-11.4)  
Waist-to-thigh ratio3,6 0.075   0.070   0.117 
Low  141 39 1  16 1  7 1  
Medium 147 69 1.6(1.0-2.5)  39 2.2(1.1-4.1)  23 2.8(1.1-7.1)  
High 127 83 1.9(1.2-3.1)  42 2.2(1.1-4.3)  24 2.5(1.0-6.3)  
Abbreviations: SIM: Specialized intestinal metaplasia; VBE: Visible Barrett’s Esophagus; LSBE: Long-segmented Barrett’s 
esophagus; BMI: Body Mass Index 
1 Adjusted for gender, WHR, cigarette use (Ever/Never) and clinic  
2 Adjusted for age, WHR, cigarette use (Ever/Never) and clinic  
3 Adjusted for age, gender, cigarette use (Ever/Never) and clinic 
4 Male Low/Medium/High: <94 cm/94-101.99cm/=102; Female Low/Medium/High: <79cm/79-87.99cm/=88 
5 Male Low/High:  <0.9/=0.9; Female Low/High: <0.8/=0.8 
6 By tertiles, Male Low/Medium/High: 0.97-1.66/1.66-1.80/1.80-2.72; Female Low/Medium/High: 1.02-1.42/1.42-1.61/1.62-2.4 
7 P-values corresponding to a trend test with the characteristic modeled as a log continuous variable for BMI, WC, WHR and WTR, 
a trend test with age modeled as a continuous variable and an overall Wald test for gender and race  
Table 3.  Odds ratios1 for Barrett’s esophagus associated with high waist-to-hip ratio2 among 
subgroups   
Subgroup 
GERD 
Controls  
SIM  VBE  LSBE 
No. 
High/Low  
No. 
High/Low 
OR 
(95% CI)  
No. 
High/Low 
OR 
(95% CI) 
No. 
High/Low 
OR 
(95% CI) 
Males  157/56  102/15 1.9(1.0-3.7)  63/8 2.2(1.0-4.9) 40/3 3.6(1.1-12.2) 
Females  137/65  50/24 1.0(0.5-1.7)  20/6 1.5(0.6-4.1) 10/1 5.4(0.7-44.8)           
Less than 50 years old  131/83  55/20 1.6(0.9-2.9)  27/8 1.9(0.8-4.5) 16/4 2.3(0.7-7.0) 
50+ years old  163/38  97/19 1.1(0.6-2.1)  56/6 1.8(0.7-4.6) 34/0 -           
Nonsmoker  145/66  50/17 1.1(0.6-2.1)  28/8 1.2(0.5-2.9) 14/1 4.7(0.6-36.8) 
Ever Smoked  149/55  102/22 1.5(0.9-2.7)  55/6 2.8(1.1-7.0) 36/3 3.9(1.1-13.3)           
BMI <25
 
65/49  19/18 1.0(0.5-2.2)  15/10 1.4(0.6-3.6) 9/2 4.0(0.8-19.7) 
BMI  25+ 243/56  133/21 1.3(0.7-2.3)  68/4 3.1(1.1-9.2) 41/2 4.1(0.9-18.8)           
Heartburn <weekly 65/31  35/11 1.1(0.5-2.4)  18/6 0.8(0.3-2.4) 10/2 1.0(0.2-5.5) 
Heartburn weekly+ 226/89  117/28 1.4(0.9-2.4)  65/8 2.7(1.2-6.1) 40/2 7.4(1.8-30.1)           
Acid regurgitation <weekly 132/97  77/34 1.1(0.7-2.0)  51/15 1.4(0.7-2.8) 30/5 3.4(1.0-12.0) 
Acid regurgitation weekly+ 100/83  54/25 1.7(0.9-3.4)  24/7 5.1(1.2-22.3) 16/3 6.4(1.0-42.4) 
Abbreviations: SIM: Specialized intestinal metaplasia; VBE: Visible Barrett’s Esophagus; LSBE: Long-segmented Barrett’s 
esophagus; BMI: Body Mass Index  
1Adjusted for clinic, as well as gender , age and cigarette smoking history  
2 High WHR defined as =0.9 for males and =0.8 for females 
Table 4. Odds ratios1 and trend tests for Barrett’s esophagus associated with measures of cigarette smoking   
SIM
 
VBE  LSBE 
Characteristic 
No. of  GERD 
Controls 
No. of Cases OR (95% CI)  No. of Cases OR (95% CI)  No. of Cases OR (95% CI) 
Smoking Categories
       
Never 212 68 1  36 1  15 1 
Ever 206 125 1.8(1.2-2.6)  61 1.6(1.0-2.6)  39 2.6(1.3-4.9)           
Nonsmoker 212 68 1  36 1  15 1 
Former 150 96 1.8(1.2-2.6)  50 1.8(1.1-2.9)  32 2.8(1.4-5.7) 
Current 56 29 1.8(1.0-3.0)  11 1.3(0.6-2.7)  7 1.8(0.7-4.9) 
Pack-years
 
Non-smoker 212 68 1  36 1  15 1 
<13.5  114 62 1.7(1.1-2.6)  31 1.7(1.0-2.8)  18 2.6(1.2-5.5) 
=13.5  92 63 1.9(1.2-2.9)  30 1.6(0.9-2.9)  21 2.5(1.2-5.5) 
Cessation2
Current smoker 56 29 1  11 1  7 1 
1-10 years 55 30 1.0(0.5-2.0)  15 1.3(0.5-3.4)  8 1.2(0.4-4.0) 
>10 years 95 66 1.1(0.6-2.0)  35 1.5(0.6-3.6)  24 2.2(0.8-5.6) 
Abbreviations: SIM: Specialized intestinal metaplasia; VBE: Visible Barrett’s Esophagus; LSBE: Long-segmented Barrett’s 
esophagus  
1Adjusted for age (<50/50+), gender, waist-to-hip ratio (low/high) and clinic 
2Among former or current smokers only  
